Gan & Lee Pharmaceuticals Receives European Commission Approval for Insulin Lispro Injection

Stock News05-14 16:34

Gan & Lee Pharmaceuticals (603087.SH) announced that the company and its European wholly-owned subsidiary, Gan & Lee Pharmaceuticals Europe GmbH, have recently received notification from the European Commission (EC). The company's product, Insulin Lispro Injection (brand name: Bysumlog®), has obtained marketing authorization in the European Union, Iceland, Liechtenstein, and Norway for the treatment of diabetes in adults and children. According to the 11th edition of the "Global Diabetes Overview" released by the International Diabetes Federation (IDF) in 2025, the number of diabetic patients aged 20-79 worldwide reached approximately 588.7 million in 2024. In Europe, the prevalence rate is 9.8%, with 65.6 million patients, accounting for about 11.1% of the global total. In 2024, diabetes-related healthcare expenditures in Europe amounted to $193 billion, with an average annual per capita expenditure of $2,951. As of the announcement date, Insulin Lispro in the European market is primarily supplied by the originator company, Eli Lilly. In 2024, Eli Lilly's global sales of Insulin Lispro were approximately $2.325 billion.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1199496588?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-14 16:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1199496588","market":"fut","top_or_hot":-1,"title":"Gan & Lee Pharmaceuticals Receives European Commission Approval for Insulin Lispro Injection","media":"Stock News","content":"<p>Gan & Lee Pharmaceuticals (603087.SH) announced that the company and its European wholly-owned subsidiary, Gan & Lee Pharmaceuticals Europe GmbH, have recently received notification from the European Commission (EC). The company's product, Insulin Lispro Injection (brand name: Bysumlog®), has obtained marketing authorization in the European Union, Iceland, Liechtenstein, and Norway for the treatment of diabetes in adults and children. According to the 11th edition of the \"Global Diabetes Overview\" released by the International Diabetes Federation (IDF) in 2025, the number of diabetic patients aged 20-79 worldwide reached approximately 588.7 million in 2024. In Europe, the prevalence rate is 9.8%, with 65.6 million patients, accounting for about 11.1% of the global total. In 2024, diabetes-related healthcare expenditures in Europe amounted to $193 billion, with an average annual per capita expenditure of $2,951. As of the announcement date, Insulin Lispro in the European market is primarily supplied by the originator company, Eli Lilly. In 2024, Eli Lilly's global sales of Insulin Lispro were approximately $2.325 billion.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gan & Lee Pharmaceuticals Receives European Commission Approval for Insulin Lispro Injection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGan & Lee Pharmaceuticals Receives European Commission Approval for Insulin Lispro Injection\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-14 16:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Gan & Lee Pharmaceuticals (603087.SH) announced that the company and its European wholly-owned subsidiary, Gan & Lee Pharmaceuticals Europe GmbH, have recently received notification from the European Commission (EC). The company's product, Insulin Lispro Injection (brand name: Bysumlog®), has obtained marketing authorization in the European Union, Iceland, Liechtenstein, and Norway for the treatment of diabetes in adults and children. According to the 11th edition of the \"Global Diabetes Overview\" released by the International Diabetes Federation (IDF) in 2025, the number of diabetic patients aged 20-79 worldwide reached approximately 588.7 million in 2024. In Europe, the prevalence rate is 9.8%, with 65.6 million patients, accounting for about 11.1% of the global total. In 2024, diabetes-related healthcare expenditures in Europe amounted to $193 billion, with an average annual per capita expenditure of $2,951. As of the announcement date, Insulin Lispro in the European market is primarily supplied by the originator company, Eli Lilly. In 2024, Eli Lilly's global sales of Insulin Lispro were approximately $2.325 billion.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"603087","symbol_name":"甘李药业","start_time":0,"source_url":"","article_id":"1199496588","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1199496588","pubTimestamp":1778747669,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Gan & Lee Pharmaceuticals (603087.SH) announced that the company and its European wholly-owned subsidiary, Gan & Lee Pharmaceuticals Europe GmbH, have recently received notification from the European...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"603087":"甘李药业","BK0239":"医药制造","IPOS":"Renaissance International IPO ETF"},"translate_title":"甘李药业赖脯胰岛素注射液获欧盟委员会批准","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"603087":1,"IPOS":1},"content_text":"Gan & Lee Pharmaceuticals (603087.SH) announced that the company and its European wholly-owned subsidiary, Gan & Lee Pharmaceuticals Europe GmbH, have recently received notification from the European Commission (EC). The company's product, Insulin Lispro Injection (brand name: Bysumlog®), has obtained marketing authorization in the European Union, Iceland, Liechtenstein, and Norway for the treatment of diabetes in adults and children. According to the 11th edition of the \"Global Diabetes Overview\" released by the International Diabetes Federation (IDF) in 2025, the number of diabetic patients aged 20-79 worldwide reached approximately 588.7 million in 2024. In Europe, the prevalence rate is 9.8%, with 65.6 million patients, accounting for about 11.1% of the global total. In 2024, diabetes-related healthcare expenditures in Europe amounted to $193 billion, with an average annual per capita expenditure of $2,951. As of the announcement date, Insulin Lispro in the European market is primarily supplied by the originator company, Eli Lilly. In 2024, Eli Lilly's global sales of Insulin Lispro were approximately $2.325 billion.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1199496588","isCrawlerRequest":true}